<![CDATA[Teclistamab Combo Earns EU Approval in Relapsed/Refractory Multiple Myeloma]]>
RegulatoryapprovedteclistamabdaratumumabPositive
AI Analysis
Summary
The European Commission approved teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma based on MajesTEC-3 study data.
Clinical Trial Data
Outcome Details
European Commission approval of teclistamab plus daratumumab combination for relapsed/refractory multiple myeloma based on MajesTEC-3 study data
Importance:8/10
Sentiment:
0.90
EU approvalmultiple myelomacombination therapyregulatory
Read the original article
Published by Cancer Network on August 24, 2026 4:30 PM